Michael Schickler - Purple Biotech Head Affairs
| PPBT Stock | USD 0.68 0.08 13.33% |
Insider
Michael Schickler is Head Affairs of Purple Biotech
| Age | 66 |
| Address | 4 Oppenheimer Street, Rehovot, Israel, 7670104 |
| Phone | 972 3 933 3121 |
| Web | https://purple-biotech.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.2814) % which means that it has lost $0.2814 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4909) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.28 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Purple Biotech's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 964.8 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 3.7 M in 2024.Similar Executives
| Found 10 records | INSIDER Age | ||
| RAC Sakai | Tempest Therapeutics | N/A | |
| Petpiboon Prasit | Tempest Therapeutics | N/A | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Gerald Goodman | Nutriband | 76 | |
| Jeffrey PharmD | Nutriband | 54 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Anne Moon | Tempest Therapeutics | N/A | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Dr Dubensky | Tempest Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.28 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MA CPA, Chief Officer | ||
| Fabien Sebille, Chief Officer | ||
| Michael Schickler, Head Affairs | ||
| LLM BSc, Vice Operations | ||
| Ido Morpurgo, VP Operations | ||
| Nir Livneh, VP Affairs |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 134.59 M | ||||
| Shares Outstanding | 26.11 M | ||||
| Shares Owned By Insiders | 3.83 % | ||||
| Shares Owned By Institutions | 9.60 % | ||||
| Number Of Shares Shorted | 297.21 K | ||||
| Price To Book | 0.47 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (120 K) |
Pair Trading with Purple Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Purple Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Purple Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Purple Stock
| 0.81 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
| 0.82 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Purple Stock
| 0.82 | RZLT | Rezolute Fiscal Year End 12th of September 2024 | PairCorr |
| 0.48 | NTRB | Nutriband Financial Report 14th of June 2024 | PairCorr |
| 0.41 | CRDL | Cardiol Therapeutics | PairCorr |
The ability to find closely correlated positions to Purple Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Purple Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Purple Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Purple Biotech to buy it.
The correlation of Purple Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Purple Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Purple Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Purple Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.Note that the Purple Biotech information on this page should be used as a complementary analysis to other Purple Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Purple Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Purple Biotech. If investors know Purple will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Purple Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Return On Assets (0.28) | Return On Equity (0.49) |
The market value of Purple Biotech is measured differently than its book value, which is the value of Purple that is recorded on the company's balance sheet. Investors also form their own opinion of Purple Biotech's value that differs from its market value or its book value, called intrinsic value, which is Purple Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Purple Biotech's market value can be influenced by many factors that don't directly affect Purple Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.